Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidutolimod + Nivolumab + Ipilimumab + Radiosurgery in CRC Liver Metastases
NCT03507699Phase 1Completed
- Sponsor
- Sheba Medical Center
- Start
- Dec 2018
- Primary completion
- Aug 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of vidutolimod in colorectal cancer (CRC) (2 arms), sponsored by Sheba Medical Center. Primary endpoint: Number of participants with serious dose-limiting treatment-related adverse events. Started Dec 2018; status: completed.
02
Drugs
vidutolimod
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03507699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507699.